285 related articles for article (PubMed ID: 32866294)
1. Drivers underpinning the malignant transformation of giant cell tumour of bone.
Fittall MW; Lyskjaer I; Ellery P; Lombard P; Ijaz J; Strobl AC; Oukrif D; Tarabichi M; Sill M; Koelsche C; Mechtersheimer G; Demeulemeester J; Tirabosco R; Amary F; Campbell PJ; Pfister SM; Jones DT; Pillay N; Van Loo P; Behjati S; Flanagan AM
J Pathol; 2020 Dec; 252(4):433-440. PubMed ID: 32866294
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic lockdown of CDKN1A (p21) and CDKN2A (p16) characterises the neoplastic spindle cell component of giant cell tumours of bone.
Giesche J; Mellert K; Geißler S; Arndt S; Seeling C; von Baer A; Schultheiss M; Marienfeld R; Möller P; Barth TF
J Pathol; 2022 Aug; 257(5):687-696. PubMed ID: 35522566
[TBL] [Abstract][Full Text] [Related]
3. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
Gong L; Bui MM; Zhang W; Sun X; Zhang M; Yi D
Histol Histopathol; 2021 Jan; 36(1):61-68. PubMed ID: 33021329
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.
Yamamoto H; Iwasaki T; Yamada Y; Matsumoto Y; Otsuka H; Yoshimoto M; Kohashi K; Taguchi K; Yokoyama R; Nakashima Y; Oda Y
Hum Pathol; 2018 Mar; 73():41-50. PubMed ID: 29241742
[TBL] [Abstract][Full Text] [Related]
5. H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone.
Amary F; Berisha F; Ye H; Gupta M; Gutteridge A; Baumhoer D; Gibbons R; Tirabosco R; O'Donnell P; Flanagan AM
Am J Surg Pathol; 2017 Aug; 41(8):1059-1068. PubMed ID: 28505000
[TBL] [Abstract][Full Text] [Related]
6. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
[TBL] [Abstract][Full Text] [Related]
7. Malignant Transformation of Giant Cell Tumour of Bone: A Review of Literature and the Experience of a Referral Centre.
Vari S; Riva F; Onesti CE; Cosimati A; Renna D; Biagini R; Baldi J; Zoccali C; Anelli V; Annovazzi A; Covello R; Ascione A; Casini B; Ferraresi V
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142631
[TBL] [Abstract][Full Text] [Related]
8. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
Yamamoto H; Ishihara S; Toda Y; Oda Y
Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
[TBL] [Abstract][Full Text] [Related]
9. Highly recurrent H3F3A mutations with additional epigenetic regulator alterations in giant cell tumor of bone.
Ogura K; Hosoda F; Nakamura H; Hama N; Totoki Y; Yoshida A; Ohashi S; Rokutan H; Takai E; Yachida S; Kawai A; Tanaka S; Shibata T
Genes Chromosomes Cancer; 2017 Oct; 56(10):711-718. PubMed ID: 28545165
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Utility of Genetic and Immunohistochemical
Wągrodzki M; Tysarowski A; Seliga K; Wojnowska A; Stepaniuk M; Castañeda Wysocka P; Makuła D; Pieńkowski A; Szostakowski B; Zub R; Rutkowski P
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055156
[TBL] [Abstract][Full Text] [Related]
11. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.
Lüke J; von Baer A; Schreiber J; Lübbehüsen C; Breining T; Mellert K; Marienfeld R; Schultheiss M; Möller P; Barth TFE
Histopathology; 2017 Jul; 71(1):125-133. PubMed ID: 28211081
[TBL] [Abstract][Full Text] [Related]
12. Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone.
Righi A; Mancini I; Gambarotti M; Picci P; Gamberi G; Marraccini C; Dei Tos AP; Simi L; Pinzani P; Franchi A
Hum Pathol; 2017 Oct; 68():128-135. PubMed ID: 28899740
[TBL] [Abstract][Full Text] [Related]
13. Anti-Histone H3.3 G34W antibody is a sensitive and highly specific immunohistochemistry marker for the diagnosis of Giant cell tumor of bone. A validation based on analysis of 198 cases from a single centre in India.
Kamble A; Hui M; Rao KN; Narayanan R; Reddy BR; Uppin SG; Chandrasekhar P
Indian J Pathol Microbiol; 2022; 65(3):617-629. PubMed ID: 35900490
[TBL] [Abstract][Full Text] [Related]
14. An extremely rare case of primary malignancy in giant cell tumor of bone, arising in the right femur and harboring H3F3A mutation.
Tsukamoto Y; Futani H; Kihara T; Watanabe T; Kumanishi S; Matsuo S; Hirota S; Ueda T; Yamamoto H; Yoshiya S
Pathol Res Pract; 2018 Sep; 214(9):1504-1509. PubMed ID: 29970305
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of histone 3 mutations in osteoclast-rich bone tumors.
Nohr E; Lee LH; Cates JM; Perizzolo M; Itani D
Hum Pathol; 2017 Oct; 68():119-127. PubMed ID: 28882701
[TBL] [Abstract][Full Text] [Related]
16. H3F3A-mutated giant cell tumour of bone without giant cells-clinical presentation, radiology and histology of three cases.
Leinauer B; Wolf E; Werner M; Baumhoer D; Breining T; Luebke AM; Maas R; Schultheiß M; von Baer A; Sufi-Siavach A; Moritz C; Geißler S; Mellert K; Möller P; Barth TFE; Jundt G
Histopathology; 2021 Nov; 79(5):720-730. PubMed ID: 33991114
[TBL] [Abstract][Full Text] [Related]
17. Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation.
Hasenfratz M; Mellert K; Marienfeld R; von Baer A; Schultheiss M; Roitman PD; Aponte-Tinao LA; Lehner B; Möller P; Mechtersheimer G; Barth TFE
Sci Rep; 2021 Mar; 11(1):5709. PubMed ID: 33707617
[TBL] [Abstract][Full Text] [Related]
18. Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma.
Venneker S; Szuhai K; Hogendoorn PCW; Bovée JVMG
Virchows Arch; 2020 Jan; 476(1):135-146. PubMed ID: 31728625
[TBL] [Abstract][Full Text] [Related]
19. H3F3A mutation as a marker of malignant giant cell tumor of the bone: A case report and review of literature.
Ratnagiri R; Uppin S
J Cancer Res Ther; 2023; 19(3):832-834. PubMed ID: 37470622
[TBL] [Abstract][Full Text] [Related]
20. The role of the tumor suppressor RUNX3 in giant cell tumor of the bone.
Han YX; Liang DY
Int J Oncol; 2012 Mar; 40(3):673-8. PubMed ID: 22076387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]